3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
304
Stomach Neoplasms
34
Neoplasm Metastasis
24
Neoplasms
16
Colorectal Neoplasms
16
Breast Neoplasms, Male
16
HER2-positive Breast Cancer
11
Inflammatory Breast Neoplasms
10
Triple Negative Breast Neoplasms
9
Esophageal Neoplasms
9
Carcinoma, Non-Small-Cell Lung
8
Brain Neoplasms
8
Rectal Neoplasms
7
Adenocarcinoma
7
Colonic Neoplasms
6
Urinary Bladder Neoplasms
5
Pathologic Complete Response
5
Biliary Tract Neoplasms
5
Urologic Neoplasms
4
Salivary Gland Neoplasms
4
Prostatic Neoplasms
4
Lung Neoplasms
4
Gallbladder Neoplasms
4
Carcinoma, Ductal, Breast
4
Recurrence
3
Pancreatic Neoplasms
3
Neoplastic Cells, Circulating
3
Multiple Myeloma
3
Meningeal Neoplasms
3
HER2-positive Gastric Cancer
3
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Advanced Unresectable or Metastatic Solid Malignancy
×
Trastuzumab
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts